|
|
Volumn 522, Issue 7554, 2015, Pages 26-28
|
|
Business: The billion-dollar biotech
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODY;
CYTIDINE;
ERYTHROPOIETIN;
GROWTH FACTOR;
MESSENGER RNA;
NUCLEIC ACID;
NUCLEOSIDE;
NUCLEOSIDE ANALOG;
PSEUDOURIDINE;
URIDINE;
BIOTECHNOLOGY;
ANEMIA;
ANTISENSE THERAPY;
ARTICLE;
BIOCHEMISTRY;
BIOTECHNOLOGY;
CANCER THERAPY;
CLINICAL LABORATORY;
COMMERCIAL PHENOMENA;
CYSTIC FIBROSIS;
DRUG INDUSTRY;
FINANCIAL MANAGEMENT;
FLEDGLING;
GENE THERAPY;
GENETIC DISORDER;
HEALTH CARE COST;
HUMAN;
IN VITRO STUDY;
INFECTION COMPLICATION;
INFLAMMATION;
NONHUMAN;
PHARMACEUTICS;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
RARE DISEASE;
RISK ASSESSMENT;
RISK FACTOR;
RNA INTERFERENCE;
STEM CELL;
ANIMAL;
BIOSYNTHESIS;
ECONOMICS;
GENETICS;
MOUSE;
PATENT;
PRIMATE;
RAT;
TRENDS;
UNITED STATES;
ANIMALS;
BIOTECHNOLOGY;
DRUG INDUSTRY;
ERYTHROPOIETIN;
HUMANS;
MASSACHUSETTS;
MICE;
PATENTS AS TOPIC;
PRIMATES;
RATS;
RNA, MESSENGER;
|
|
EID: 84930673065
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/522026a Document Type: Article |
|
Times cited : (12)
|
|
References (8)
|
